• Publications
  • Influence
Complement Factor H Polymorphism in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a major cause of blindness in the elderly. We report a genome-wide screen of 96 cases and 50 controls for polymorphisms associated with AMD. Among 116,204Expand
  • 2,969
  • 99
Complement factor H polymorphism in age-related macular degeneration.
Age-related macular degeneration (AMD) is a major cause of blindness in the elderly. We report a genome-wide screen of 96 cases and 50 controls for polymorphisms associated with AMD. Among 116,204Expand
  • 1,345
  • 77
  • PDF
A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.
Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whether any treatment is clinically effective remains uncertain. WeExpand
  • 1,016
  • 65
International Standards for Neurological and Functional Classification of Spinal Cord Injury
International Standards for Neurological and Functional Classification of Spinal Cord Injury
  • 1,885
  • 62
Renal impairment and outcomes in heart failure: systematic review and meta-analysis.
OBJECTIVES We estimated the prevalence of renal impairment in heart failure (HF) patients and the magnitude of associated mortality risk using a systematic review of published studies. BACKGROUNDExpand
  • 751
  • 31
Administration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury: Results of the Third National Acute Spinal Cord Injury
Objective.\p=m-\Tocompare the efficacy of methylprednisolone administered for 24 hours with methyprednisolone administered for 48 hours or tirilazad mesylate administered for 48 hours in patientsExpand
  • 422
  • 31
  • PDF
Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study.
The 1-year follow-up data of a multicenter randomized controlled trial of methylprednisolone (30 mg/kg bolus and 5.4 mg/kg/hr for 23 hours) or naloxone (5.4 mg/kg bolus and 4.0 mg/kg/hr for 23 hours)Expand
  • 658
  • 24
  • PDF
Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury
OBJECTIVE To compare the efficacy of methylprednisolone administered for 24 hours with methyprednisolone administered for 48 hours or tirilazad mesylate administered for 48 hours in patients withExpand
  • 527
  • 20
Steroids for acute spinal cord injury.
  • M. Bracken
  • Medicine
  • The Cochrane database of systematic reviews
  • 18 January 2012
BACKGROUND Acute spinal cord injury is a devastating condition typically affecting young people, mostly males. Steroid treatment in the early hours after the injury is aimed at reducing the extent ofExpand
  • 299
  • 20
Efficacy of methylprednisolone in acute spinal cord injury.
A multicenter double-blind randomized trial was conducted to examine the efficacy of a high dose of methylprednisolone (1,000-mg bolus and daily thereafter for ten days) compared with a standard doseExpand
  • 460
  • 17